Nordic Nanovector ASA – Results for the First Quarter 2019
Oslo, Norway, 23 May 2019 Nordic Nanovector ASA (OSE: NANO) announces its results for the first quarter 2019. A presentation by the company’s senior management team will take place today in Oslo at 08:30 CEST, see details below. Eduardo Bravo, CEO, commented: “As we advance the clinical development programmes with Betalutin®, including PARADIGME, we are also beginning to initiate some of the other pre-commercialisation activities, such as manufacturing, that are crucial to ensure that we can submit our regulatory filing in a timely and efficient manner. The recent fundraising is